Natural history of chronic hepatitis B and C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue SUPPL., 1999, Pages

  Imperial, Joanne C ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Cirrhosis; Transplantation; Viral hepatitis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; RIBAVIRIN;

ADULT; AGE; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE COURSE; FEMALE; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNE STATUS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; VIRUS CARRIER; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0033044092     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01903.x     Document Type: Article

References (30)

1. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8.
2. Lok ASF, Lai CL, Wu PC, Leung EKY, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-43.
3. Liaw YF, Tai DI, Chu CM et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8: 493-6.
4. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae: Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch. Intern. Med. 1990; 150: 1051-4.
5. De Jongh FE, Janssen HLA, De Man RA et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
6. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26: 1338-42.
7. Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hapatitis and Liver Disease. Orlando: Grune and Stratton, 1984; 209-24.
8. Fowler MJF, Greenfield C, Chu CM et al. Integration of HBV-DNA may not be a prerequisite for the maintenance of the state of malignant transformation. J. Hepatol. 1986; 2: 218-29.
9. Todo S, Demetrius AJ, Thiel DV, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
10. Chung HT, Lai CL, Wu PC, Lok AS. Synergism of chronic alcoholism and hepatitis B infection in liver disease. J. Gastroenterol. Hepatol. 1989; 4: 11-16.
11. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 1990; 323: 295-301.
12. Wu PC, Lok AS, Lau JY, Lauder IJ, Lai CL. Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-alpha therapy. Am. J. Clin. Pathol. 1992; 98: 402-7.
13. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer 1998; 82: 827-35.
14. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-8.
15. McQuillan GM, Alter MJ, Moyer LA, Lamber SB, Hargolis HS. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Puercell RH, Gerin JL, Verme G et al., eds. Viral Hepatitis and Liver Disease. Turin; Edizioni Minerva Medica, 1997; 267-70.
16. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin. Liver Dis. 1997; 1: 559-68.
17. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin. Liver Dis. 1997; 1: 587-602.
18. Tong MJ, El-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 1995; 332: 1463-6.
19. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
20. Takahashi M, Yamada G, Miyamoto R et al. Natural history of chronic hepatitis C. Am. J. Gastroenterol. 1993; 88: 240-3.
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
22. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 1993; 6: 602-10.
23. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997; 25: 1527-38.
24. Gholson CF, Morgan K, Catinis G et al. Chronic hepatitis C with normal aminotransferase levels: A clinical histologic study. Am. J. Gastroenterol. 1997; 92: 1788-92.
25. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C. A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
26. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 1996; 24: 778-89.
27. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl J. Med. 1998; 339: 1585-92.
28. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
29. Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J. Hepatol. 1997; 27: 201-5.
30. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.